Dov Md Goldstein Sells 27,000 Shares of BioAge Labs (NASDAQ:BIOA) Stock

BioAge Labs, Inc. (NASDAQ:BIOA) CFO Dov Md Goldstein sold 27,000 shares of the business’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total transaction of $531,900.00. Following the sale, the chief financial officer owned 22,408 shares in the company, valued at approximately $441,437.60. This trade represents a 54.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

BioAge Labs Stock Down 6.2%

Shares of BIOA stock traded down $1.41 during trading hours on Thursday, hitting $21.51. 885,351 shares of the company’s stock traded hands, compared to its average volume of 1,150,796. The stock’s fifty day simple moving average is $11.68 and its two-hundred day simple moving average is $7.43. BioAge Labs, Inc. has a 12-month low of $2.88 and a 12-month high of $24.00. The stock has a market cap of $771.13 million, a price-to-earnings ratio of -14.15 and a beta of 1.38.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Thursday, November 6th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.11. The company had revenue of $2.05 million during the quarter.

Institutional Trading of BioAge Labs

Several large investors have recently added to or reduced their stakes in BIOA. Police & Firemen s Retirement System of New Jersey purchased a new stake in BioAge Labs during the second quarter valued at approximately $27,000. Russell Investments Group Ltd. bought a new stake in BioAge Labs during the third quarter valued at about $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after buying an additional 5,976 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in shares of BioAge Labs during the 2nd quarter valued at approximately $57,000. Finally, Intech Investment Management LLC purchased a new stake in BioAge Labs in the 2nd quarter worth approximately $60,000.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BIOA. Citigroup boosted their target price on BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Wall Street Zen cut shares of BioAge Labs from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Thursday, October 30th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $15.00.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.